Discovery of Potent and Selective Antibody–Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization

[Image: see text] Targeted antimitotic agents are a promising class of anticancer therapies. Herein, we describe the development of a potent and selective antimitotic Eg5 inhibitor based antibody–drug conjugate (ADC). Preliminary studies were performed using proprietary Eg5 inhibitors which were con...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:ACS Med Chem Lett
Autores principales: Karpov, Alexei S., Nieto-Oberhuber, Cristina M., Abrams, Tinya, Beng-Louka, Edwige, Blanco, Enrique, Chamoin, Sylvie, Chene, Patrick, Dacquignies, Isabelle, Daniel, Dylan, Dillon, Michael P., Doumampouom-Metoul, Lionel, Drosos, Nikolaos, Fedoseev, Pavel, Furegati, Markus, Granda, Brian, Grotzfeld, Robert M., Hess Clark, Suzanna, Joly, Emilie, Jones, Darryl, Lacaud-Baumlin, Marion, Lagasse-Guerro, Stephanie, Lorenzana, Edward G., Mallet, William, Martyniuk, Piotr, Marzinzik, Andreas L., Mesrouze, Yannick, Nocito, Sandro, Oei, Yoko, Perruccio, Francesca, Piizzi, Grazia, Richard, Etienne, Rudewicz, Patrick J., Schindler, Patrick, Velay, Mélanie, Venstrom, Kristine, Wang, Peiyin, Zurini, Mauro, Lafrance, Marc
Formato: Artigo
Lenguaje:Inglês
Publicado: American Chemical Society 2019
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6912867/
https://ncbi.nlm.nih.gov/pubmed/31857845
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.9b00468
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares